Abeona Therapeutics Updates on Zevaskyn Launch Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy ABEO?
Abeona Therapeutics announced an update on the building momentum in the Company's launch of FDA-approved Zevaskyn, a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, RDEB. Following the optimization of a release assay in 2025, Zevaskyn commercial launch activities commenced in the fourth quarter, with the first patient treatment completed in December prior to a mandatory scheduled facility shutdown. Since resuming manufacturing in late January 2026, multiple biopsies have been collected, a patient has completed treatment with Zevaskyn, and there are ongoing manufacturing runs. Additional biopsies are scheduled for the remainder of this quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABEO
Wall Street analysts forecast ABEO stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.160
Low
20.00
Averages
25.17
High
28.00
Current: 5.160
Low
20.00
Averages
25.17
High
28.00
About ABEO
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abeona Launches First Gene Therapy ZEVASKYN for RDEB
- FDA-Approved Innovation: Abeona Therapeutics has launched ZEVASKYN (prademagene zamikeracel), the first autologous gene therapy for treating recessive dystrophic epidermolysis bullosa (RDEB), marking a significant breakthrough in addressing severe skin diseases and is expected to greatly improve patients' quality of life.
- Increased Market Acceptance: ZEVASKYN has secured coverage from major commercial payers, including United Healthcare, Cigna, and Aetna, covering 80% of lives, indicating strong early market acceptance and anticipated sustained demand growth for the therapy.
- Manufacturing and Treatment Progress: Since resuming production in January 2026, Abeona has completed multiple biopsies and successfully treated patients, demonstrating positive advancements in establishing a stable treatment process and patient influx, which is expected to further enhance market confidence.
- Coding System Established: The CMS has established a permanent HCPCS J-code (J3389) for ZEVASKYN effective January 1, 2026, which will streamline medical billing and reimbursement processes, further promoting the therapy's market adoption and application.
See More
Netflix Highlights a Rare Disease While Pearl Jam's Lead Singer Raises Funds for a Cure.
Nonprofit's Approach: A nonprofit organization is focusing on finding a cure for Epidermolysis Bullosa, a group of rare genetic skin disorders, by adopting a venture-capital-like strategy rather than traditional charity methods.
Goal Timeline: The organization aims to achieve its goal of finding a cure by the end of the decade.
See More
Abeona Therapeutics Grants Equity Awards to New Employees
- Equity Award Program: On January 31, 2026, Abeona Therapeutics granted a total of 28,676 restricted shares to seven new employees as a material inducement for employment, aimed at enhancing the company's competitive edge in the biopharmaceutical sector.
- Vesting Conditions: The equity awards will vest one-third annually on each anniversary of the grant date, ensuring that employees remain with the company for three years, thereby increasing employee loyalty and motivation.
- Company Background: Abeona is a commercial-stage biopharmaceutical company focused on cell and gene therapies, with ZEVASKYN® being the first autologous cell-based gene therapy for treating serious diseases, showcasing its unique market value.
- Market Outlook: The company is developing adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical needs, which could further expand its market share through innovative product lines.
See More
Analysis of High Insider Ownership Growth Companies in the U.S.
- High Insider Ownership: Super Micro Computer boasts 13.9% insider ownership while achieving 50.7% earnings growth, indicating strong performance and future growth potential in the tech sector.
- Profitability Improvement: Abeona Therapeutics recently became profitable with 10.3% insider ownership and is forecasted to grow revenue by 42.5% annually, enhancing its competitive position in gene and cell therapy.
- Market Expansion Potential: Streamex Corp. has 16.1% insider ownership and, despite a financial loss of $15.58 million, is projected to grow revenue by over 100% annually, showcasing its innovative capabilities in asset tokenization.
- Earnings Growth Expectations: Fiverr International, with 11.6% insider ownership, reported a net income of $5.54 million in Q3 2025, with projected earnings growth of 47.5% per year, reflecting strong momentum in the global online marketplace.
See More
Abeona Grants 79,584 Restricted Stock Awards to New Employees
- Incentive Measures: On December 30, 2025, Abeona Therapeutics granted a total of 79,584 restricted stock awards to seven new employees as a significant inducement for employment, aimed at attracting and retaining key talent to support the company's growth.
- Equity Structure: According to Nasdaq listing rules, the awarded shares will vest annually on the anniversary of the grant date, ensuring employee retention over three years, which enhances team stability and execution capability.
- Company Background: Abeona focuses on developing cell and gene therapies, particularly its ZEVASKYN® product, which is the first autologous cell-based gene therapy for treating severe skin diseases, showcasing the company's innovative potential in the biopharmaceutical sector.
- Market Outlook: Through this equity incentive, Abeona not only enhances employee loyalty but also potentially increases its attractiveness in the highly competitive biopharmaceutical market, aiding the company in achieving its long-term growth objectives.
See More
Abeona Grants 79,584 Restricted Stock Awards to New Employees
- Incentive Measures: On December 30, 2025, Abeona Therapeutics granted a total of 79,584 restricted stock awards to seven new employees, aimed at attracting and retaining talent, which is expected to enhance the company's competitive position in the biopharmaceutical sector.
- Vesting Arrangement: The restricted stock will vest annually on each anniversary of the grant date, ensuring that employees remain with the company for three years, thereby increasing employee loyalty and engagement.
- Compliance: This stock grant complies with Nasdaq Listing Rule 5635(c)(4), indicating that the company adheres to industry standards in its incentive mechanisms, which can bolster investor confidence.
- Company Background: Abeona focuses on developing cell and gene therapies, particularly its ZEVASKYN® product as an innovative solution for treating serious diseases, and the talent incentives are expected to further drive R&D advancements in the future.
See More
Abeona Launches First Gene Therapy ZEVASKYN for RDEB
- FDA-Approved Innovation: Abeona Therapeutics has launched ZEVASKYN (prademagene zamikeracel), the first autologous gene therapy for treating recessive dystrophic epidermolysis bullosa (RDEB), marking a significant breakthrough in addressing severe skin diseases and is expected to greatly improve patients' quality of life.
- Increased Market Acceptance: ZEVASKYN has secured coverage from major commercial payers, including United Healthcare, Cigna, and Aetna, covering 80% of lives, indicating strong early market acceptance and anticipated sustained demand growth for the therapy.
- Manufacturing and Treatment Progress: Since resuming production in January 2026, Abeona has completed multiple biopsies and successfully treated patients, demonstrating positive advancements in establishing a stable treatment process and patient influx, which is expected to further enhance market confidence.
- Coding System Established: The CMS has established a permanent HCPCS J-code (J3389) for ZEVASKYN effective January 1, 2026, which will streamline medical billing and reimbursement processes, further promoting the therapy's market adoption and application.
See More
Netflix Highlights a Rare Disease While Pearl Jam's Lead Singer Raises Funds for a Cure.
Nonprofit's Approach: A nonprofit organization is focusing on finding a cure for Epidermolysis Bullosa, a group of rare genetic skin disorders, by adopting a venture-capital-like strategy rather than traditional charity methods.
Goal Timeline: The organization aims to achieve its goal of finding a cure by the end of the decade.
See More
Abeona Therapeutics Grants Equity Awards to New Employees
- Equity Award Program: On January 31, 2026, Abeona Therapeutics granted a total of 28,676 restricted shares to seven new employees as a material inducement for employment, aimed at enhancing the company's competitive edge in the biopharmaceutical sector.
- Vesting Conditions: The equity awards will vest one-third annually on each anniversary of the grant date, ensuring that employees remain with the company for three years, thereby increasing employee loyalty and motivation.
- Company Background: Abeona is a commercial-stage biopharmaceutical company focused on cell and gene therapies, with ZEVASKYN® being the first autologous cell-based gene therapy for treating serious diseases, showcasing its unique market value.
- Market Outlook: The company is developing adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical needs, which could further expand its market share through innovative product lines.
See More
Analysis of High Insider Ownership Growth Companies in the U.S.
- High Insider Ownership: Super Micro Computer boasts 13.9% insider ownership while achieving 50.7% earnings growth, indicating strong performance and future growth potential in the tech sector.
- Profitability Improvement: Abeona Therapeutics recently became profitable with 10.3% insider ownership and is forecasted to grow revenue by 42.5% annually, enhancing its competitive position in gene and cell therapy.
- Market Expansion Potential: Streamex Corp. has 16.1% insider ownership and, despite a financial loss of $15.58 million, is projected to grow revenue by over 100% annually, showcasing its innovative capabilities in asset tokenization.
- Earnings Growth Expectations: Fiverr International, with 11.6% insider ownership, reported a net income of $5.54 million in Q3 2025, with projected earnings growth of 47.5% per year, reflecting strong momentum in the global online marketplace.
See More
Abeona Grants 79,584 Restricted Stock Awards to New Employees
- Incentive Measures: On December 30, 2025, Abeona Therapeutics granted a total of 79,584 restricted stock awards to seven new employees as a significant inducement for employment, aimed at attracting and retaining key talent to support the company's growth.
- Equity Structure: According to Nasdaq listing rules, the awarded shares will vest annually on the anniversary of the grant date, ensuring employee retention over three years, which enhances team stability and execution capability.
- Company Background: Abeona focuses on developing cell and gene therapies, particularly its ZEVASKYN® product, which is the first autologous cell-based gene therapy for treating severe skin diseases, showcasing the company's innovative potential in the biopharmaceutical sector.
- Market Outlook: Through this equity incentive, Abeona not only enhances employee loyalty but also potentially increases its attractiveness in the highly competitive biopharmaceutical market, aiding the company in achieving its long-term growth objectives.
See More
Abeona Grants 79,584 Restricted Stock Awards to New Employees
- Incentive Measures: On December 30, 2025, Abeona Therapeutics granted a total of 79,584 restricted stock awards to seven new employees, aimed at attracting and retaining talent, which is expected to enhance the company's competitive position in the biopharmaceutical sector.
- Vesting Arrangement: The restricted stock will vest annually on each anniversary of the grant date, ensuring that employees remain with the company for three years, thereby increasing employee loyalty and engagement.
- Compliance: This stock grant complies with Nasdaq Listing Rule 5635(c)(4), indicating that the company adheres to industry standards in its incentive mechanisms, which can bolster investor confidence.
- Company Background: Abeona focuses on developing cell and gene therapies, particularly its ZEVASKYN® product as an innovative solution for treating serious diseases, and the talent incentives are expected to further drive R&D advancements in the future.
See More
